logo image

Adalimumab information from DrugsUpdate  

See Available Brands of Adalimumab in India

Adalimumab, a TNF-alpha (Tumor Necrosis Factor-Alpha), blocker is indicated for the reduction of inflammation. The drug is prescribed for the treatment of psoriatic arthritis, plaque psoriasis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis. Adalimumab is also prescribed for treatment of Crohn’s disease patients who are unresponsive to treatment procedures.

Pharmacodynamics

Adalimumab is a TNF-alpha receptor blocker. The drug selectively binds with p55 and p75 cell surface proteins present in the receptors. The drug does not bind or block TNF-beta receptors.

Pharmacokinetics

The Cmax and Tmax of Adalimumab are 4.7 ± 1.6 μg/mL and 131 ± 56 hours respectively, after administration of a single dose (40 mg), subcutaneous administration of Adalimumab. The bioavailability of Adalimumab is 64%.

Adalimumab Indications / Adalimumab Uses

No information available

Adalimumab Adverse Reactions / Adalimumab Side Effects

Infection, chest pain with tachypnoea and wheezing, easy bruising, fatigue, lymphadenopathy, hair loss, mouth sores and lupus-like reactions over cheeks and nose. Common, non-serious adverse events are injection-site reaction, headache, sinus pain with mild abdominal pain.

Precautions

Do not take use Adalimumab, if you have an active or recent history of infections including Hepatitis B, skin wounds, congestive heart failure, lupus, history of tuberculosis, multiple sclerosis, myasthenia gravis, Guillain-Barre syndrome.

Special Precautions

No information available

Other Drug Interactions

No information available

Other Interactions

No information available

Dosage

Adults:
For Rheumatoid Arthritis, Ankylosing Spondylitis and
Psoriatic Arthritis:
40 mg subcutaneous injections, every other week. Dosing interval should be reduced to every week, if methotrexate, salicylates, NSAIDS, corticosteroids are not prescribed concomitantly.

For Crohn's Disease -- Acute:
Week 1: 160 mg, SC, on Day 1. The dosage can be divided as 4 injection on Day 1 or twice daily for 2 days.
Week 2: 80 mg, SC on Day 15.
 
Maintenance dose: From 4th week onwards (Day 29th), 40 mg, SC, every other week.
 
For Crohn's Disease -- Maintenance:
Week 1: 160 mg, SC, on Day 1. The dosage can be divided as 4 injection on Day 1 or twice daily for 2 days.
Week 2: 80 mg, SC on Day 15.
 
Maintenance dose: From 4th week onwards (Day 29th), 40 mg, SC, every other week.
 
For Plaque Psoriasis:
Start with 80 mg, subcutaneously for one week. The maintenance dose is 40 mg, SC, every other week after the initial dose.
 
Pediatric Dosage:
For Juvenile Idiopathic Arthritis:
4 to 17 years: No credible clinical trial data are available for pediatric patients (below 15 kg).

15 kg to >30 kg: 20 mg Adalimumab injection, SC, every other week

<30 kg: 40 mg Adalimumab injection, SC, every other week

Food(before/after)

No information available

List of Contraindications

Adalimumab and Pregnancy

USFDA pregnancy category B. Adalimumab may not cause harm to an unborn foetus. Before Adalimumab treatment, patient should discuss with the physician if they are planning for a pregnancy.

Adalimumab and Lactation

It is unclear whether the drug could pass through the breast milk to a breast feeding baby. Consult your physician before taking Adalimumab, if you are nursing mother.

Adalimumab and Children

Adalimumab is contraindicated in children below 4 years old. The drug should not be given to individuals younger than 18 years old, without prescription. Before Adalimumab administration, all prescribed vaccinations should be done in children.

Adalimumab and Geriatic

No specific information

Adalimumab and Other Contraindications

No specific information

Storage

Refrigerate but do not freeze. Use cooler box with an ice pack, if you are travelling with the pre-filled syringe.

Lab interference

Refrigerate but do not freeze. Use cooler box with an ice pack, if you are travelling with the pre-filled syringe.

© 2011-2018 DrugsUpdate.com. Disclaimer | Site Map

Feedback